Initiating coverage of Insight Molecular Diagnostics Inc. with a Hold rating due to upcoming catalysts and pending FDA submission for GraftAssureDx kidney transplant assay. IMDX's decentralized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback